Von Willebrand disease: Advances in pathogenetic understanding,diagnosis, and therapy

Blood

Volumn 122, Issue 23, 2013, Pages 3735-3740

  Lillicrap, David ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DESMOPRESSIN; RECOMBINANT VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR;

BLOOD CLOTTING TEST; CLINICAL ASSESSMENT TOOL; CLINICAL CLASSIFICATION; CLINICAL TRIAL (TOPIC); GENETIC ANALYSIS; HUMAN; MOLECULAR PATHOLOGY; PHENOTYPE; PRIORITY JOURNAL; REVIEW; VON WILLEBRAND DISEASE;

EID: 84891065154     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-06-498303     Document Type: Review

References (54)

1. Ginsburg D, Handin RI, Bonthron DT, et al. Human von Willebrand factor (vWF): isolation of complementary DNA (cDNA) clones and chromosomal localization. Science. 1985; 228(4706):1401-1406.
2. Lynch DC, Zimmerman TS, Collins CJ, et al. Molecular cloning of cDNA for human von Willebrand factor: authentication by a new method. Cell. 1985; 41(1):49-56.
3. Sadler JE, Shelton-Inloes BB, Sorace JM, et al. Cloning and characterization of two cDNAs coding for human von Willebrand factor. Proc Natl Acad Sci U S A. 1985;82(19):6394-6398.
4. Verweij CL, de Vries CJ, Distel B, et al. Construction of cDNA coding for human von Willebrand factor using antibody probes for colony-screening and mapping of the chromosomal gene. Nucleic Acids Res. 1985; 13(13):4699-4717.
5. Bowman M, Hopman WM, Rapson D, Lillicrap D, James P. The prevalence of symptomatic von Willebrand disease in primary care practice. J Thromb Haemost. 2010;8(1):213-216.
6. Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand's disease. Blood. 1987;69(2):454-459.
7. Bloom AL. von Willebrand factor: clinical features of inherited and acquired disorders. Mayo Clin Proc. 1991;66(7):743-751.
8. Sadler JE, Budde U, Eikenboom JC, et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost. 2006;4(10):2103-2114.
9. Zhou Y-F, Eng ET, Zhu J, et al. Sequence and structure relationships within von Willebrand factor. Blood. 2012;120(2):449-458.
10. Jacobi PM, Gill JC, Flood VH, et al. Intersection of mechanisms of type 2A VWD through defects in VWF multimerization, secretion, ADAMTS-13 susceptibility, and regulated storage. Blood. 2012; 119(19):4543-4553.
11. Pruss CM, Golder M, Bryant A, et al. Use of a mouse model to elucidate the phenotypic effects of the von Willebrand factor cleavage mutants, Y1605A/M1606A and R1597W. J Thromb Haemost. 2012;10(5):940-950.
12. Federici AB, Mannucci PM, Castaman G, et al. Clinical and molecular predictors of thrombocytopenia and risk of bleeding in patients with von Willebrand disease type 2B: A cohort study of 67 patients. Blood. 2009;113:526-534.
13. Rayes J, Hollestelle MJ, Legendre P, et al. Mutation and ADAMTS13-dependent modulation of disease severity in a mouse model for von Willebrand disease type 2B. Blood. 2010;115(23): 4870-4877.
14. Golder M, Pruss CM, Hegadorn C, et al. Mutationspecific hemostatic variability in mice expressing common type 2B von Willebrand disease substitutions. Blood. 2010;115(23):4862-4869.
15. Othman M. Platelet-type von Willebrand disease and type 2B von Willebrand disease: a story of nonidentical twins when two different genetic abnormalities evolve into similar phenotypes. Semin Thromb Hemost. 2007;33(8):780-786.
16. Ribba AS, Loisel I, Lavergne JM, et al. Ser968Thr mutation within the A3 domain of von Willebrand factor (VWF) in two related patients leads to a defective binding of VWF to collagen. Thromb Haemost. 2001;86:848-854.
17. Riddell A, Gomez K, Millar C, et al. Characterisation of W1745C and S1783A, two novel collagen binding defects in the A3 domain of von Willebrand factor. Blood. 2009;114: 3489-3496.
18. Flood VH, Gill JC, Christopherson PA, et al. Critical von Willebrand factor A1 domain residues influence type 6 collagen binding. J Thromb Haemost. 2012;10(7):1417-1424.
19. Mazurier C, Goudemand J, Hilbert L, et al. Type 2N von Willebrand disease: clinical manifestations, pathophysiology, laboratory diagnosis and molecular biology. Best Pract Res Clin Haematol. 2001;14(2):337-347.
20. Eikenboom JC. Congenital von Willebrand disease type 3: clinical manifestations, pathophysiology and molecular biology. Best Pract Res Clin Haematol. 2001;14:365-379.
21. Bowman M, Tuttle A, Notley C, et al. The genetics of Canadian type 3 von Willebrand Disease (VWD): further evidence for co-dominant inheritance of mutant alleles. J Thromb Haemost. 2013;11:512-520.
22. Ngo KY, Glotz VT, Koziol JA, et al. Homozygous and heterozygous deletions of the von Willebrand factor gene in patients and carriers of severe von Willebrand disease. Proc Natl Acad Sci U S A. 1988;85(8):2753-2757.
23. Shelton-Inloes BB, Chehab FF, Mannucci PM, Federici AB, Sadler JE. Gene deletions correlate with the development of alloantibodies in von Willebrand disease. J Clin Invest. 1987;79(5): 1459-1465.
24. James PD, Lillicrap D, Mannucci PM. Alloantibodies in von Willebrand disease. Blood. 2013;122:636-640.
25. James PD, Notley C, Hegadorn C, et al. The mutational spectrum of type 1 von Willebrand disease: results from a Canadian cohort study. Blood. 2007;109(1):145-154.
26. Goodeve A, Eikenboom J, Castaman G, et al. Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD). Blood. 2007;109(1):112-121.
27. Cumming A, Grundy P, Keeney S, et al. An investigation of the von Willebrand factor genotype in UK patients diagnosed to have type 1 von Willebrand disease. Thromb Haemost. 2006; 96(5):630-641.
28. Bellissimo DB, Christopherson PA, Flood VH, et al. Von Willebrand factor mutations and new sequence variations identified in healthy controls are more frequent in the African-American population. Blood. 2012;119:2135-2140.
29. Othman M, Chirinian Y, Brown C, et al. Functional characterization of a 13 bp deletion (c.-1522- 1510del13) in the promoter of the von Willebrand factor gene in type 1 von Willebrand disease. Blood. 2010;116(18):3645-3652.
30. Eikenboom J, Hilbert L, Ribba AS, et al. Expression of 14 von Willebrand factor mutations identified in patients with type 1 von Willebrand disease from the MCMDM-1VWD study. J Thromb Haemost. 2009;7(8):1304-1312.
31. Haberichter SL, Castaman G, Budde U, et al. Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD). Blood. 2008;111(10): 4979-4985.
32. Haberichter SL, Balistreri M, Christopherson P, et al. Assay of the von Willebrand factor (VWF) propeptide to identify patients with type 1 von Willebrand disease with decreased VWF survival. Blood. 2006;108(10):3344-3351.
33. Starke RD, Paschalaki KE, Dyer CEF, et al. Cellular and molecular basis of von Willebrand disease: studies on blood outgrowth endothelial cells. Blood. 2013;121(14):2773-2784.
34. Wang J-W, Bouwens EAM, Pintao MC, et al. Analysis of the storage and secretion of von Willebrand factor in blood outgrowth endothelial cells derived from patients with von Willebrand disease. Blood. 2013;121(14):2762-2772.
35. Gill JC, Endres-Brooks J, Bauer PJ, Marks WJ Jr, Montgomery RR. The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood. 1987;69(6):1691-1695.
36. Smith NL, Chen MH, Dehghan A, et al. Novel associations of multiple genetic loci with plasma levels of factor 7, factor 8, and von Willebrand factor: The CHARGE (Cohorts for Heart and Aging Research in Genome Epidemiology) Consortium. Circulation. 2010;121(12): 1382-1392.
37. Rydz N, Swystun LL, Notley C, et al. The C-type lectin receptor CLEC4M binds, internalizes and clears von Willebrand factor and contributes to the variation in plasma von Willebrand factor levels. Blood. 2013;121:5228-5237.
38. Rydz N, James PD. The evolution and value of bleeding assessment tools. J Thromb Haemost. Prepublished online ahead of print September 13, 2012.
39. Bowman M, Mundell G, Grabell J, et al. Generation and validation of the Condensed MCMDM-1VWD bleeding questionnaire for von Willebrand disease. J Thromb Haemost. 2008; 6(12):2062-2066.
40. Tosetto A, Rodeghiero F, Castaman G, et al. A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD). J Thromb Haemost. 2006;4(4):766-773.
41. Flood VH, Gill JC, Morateck PA, et al. Gain-offunction GPIb ELISA assay for VWF activity in the Zimmerman Program for the Molecular and Clinical Biology of VWD. Blood. 2011;117(6): e67-74.
42. Lawrie AS, Stufano F, Canciani MT, et al. A comparative evaluation of a new automated assay for von Willebrand factor activity. Haemophilia. 2013;19(2):338-342.
43. Flood VH, Gill JC, Morateck PA, et al. Common VWF exon 28 polymorphisms in African Americans affecting the VWF activity assay by ristocetin cofactor. Blood. 2010;116(2):280-286.
44. Flood VH, Friedman KD, Gill JC, et al. No increase in bleeding identified in type 1 VWD subjects with D1472H sequence variation. Blood. 2013;121(18):3742-3744.
45. Flood VH, Gill JC, Christopherson PA, et al. Comparison of type 1, type 3 and type 6 collagen binding assays in diagnosis of von Willebrand disease. J Thromb Haemost. 2012;10(7): 1425-1432.
46. Mannucci PM. How I treat patients with von Willebrand disease. Blood. 2001;97(7): 1915-1919.
47. Rodeghiero F, Castaman G, Tosetto A. How I treat von Willebrand disease. Blood. 2009;114(6): 1158-1165.
48. Federici AB. The use of desmopressin in von Willebrand disease: the experience of the first 30 years (1977-2007). Haemophilia. 2008; 14(Suppl 1):5-14.
49. Castaman G, Goodeve A, Eikenboom J. Principles of care for the diagnosis and treatment of von Willebrand disease. Haematologica. 2013; 98(5):667-674.
50. Kingman CEC, Kadir RA, Lee CA, Economides DL. The use of levonorgestrel-releasing intrauterine system for treatment of menorrhagia in women with inherited bleeding disorders. BJOG. 2004;111(12):1425-1428.
51. Budde U, Metzner HJ, Müller H-G. Comparative analysis and classification of von Willebrand factor/factor 8 concentrates: impact on treatment of patients with von Willebrand disease. Semin Thromb Hemost. 2006;32(6):626-635.
52. Berntorp E. Prophylaxis in von Willebrand disease. Haemophilia. 2008;14(Suppl 5):47-53.
53. Mannucci P, Kempton C, Millar C, et al. Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective clinical trial. Blood. 2013;122: 648-657.
54. De Meyer SF, Vanhoorelbeke K, Chuah MK, et al. Phenotypic correction of von Willebrand disease type 3 blood-derived endothelial cells with lentiviral vectors expressing von Willebrand factor. Blood. 2006;107(12):4728-4736.